Shares of Renalytix Plc (LON:RENX – Get Free Report) shot up 30.1% on Tuesday . The company traded as high as GBX 6 and last traded at GBX 5.40. Approximately 4,418,656 shares were traded during trading, an increase of 374% from the average session volume of 931,928 shares. The stock had previously closed at GBX 4.15.
Renalytix Stock Up 2.5%
The firm has a 50 day moving average price of GBX 3.47 and a 200-day moving average price of GBX 2.65. The firm has a market cap of £24.19 million, a price-to-earnings ratio of -1.38 and a beta of 1.81. The company has a debt-to-equity ratio of -483.33, a current ratio of 1.57 and a quick ratio of 2.42.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Further Reading
- Five stocks we like better than Renalytix
- This Corner of the Market Is Outperforming the Benchmark—And It’s Not AI
- Victoria’s Secret’s Comeback Is Real—The Stock’s Problem Is Different
- Apple Unveils Foldable iPhone, But Stock’s Muted Reaction Raises Questions
- Palantir’s New U.S. Army Contract Brings It Closer to Owning the Full Battlefield System
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
